Compare · CELC vs DGX
CELC vs DGX
Side-by-side comparison of Celcuity Inc. (CELC) and Quest Diagnostics Incorporated (DGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CELC and DGX operate in Medical Specialities (Health Care), so they compete in similar markets.
- DGX is the larger of the two at $20.96B, about 3.6x CELC ($5.75B).
- Over the past year, CELC is up 965.3% and DGX is up 6.1% - CELC leads by 959.2 points.
- DGX has been more active in the news (15 items in the past 4 weeks vs 2 for CELC).
- DGX has more recent analyst coverage (25 ratings vs 13 for CELC).
- Company
- Celcuity Inc.
- Quest Diagnostics Incorporated
- Price
- $118.67-1.17%
- $189.15-3.00%
- Market cap
- $5.75B
- $20.96B
- 1M return
- +9.79%
- -4.16%
- 1Y return
- +965.31%
- +6.12%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 2
- 15
- Recent ratings
- 13
- 25
Celcuity Inc.
Celcuity Inc., a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Latest CELC
- Citizens initiated coverage on Celcuity with a new price target
- SEC Form 4 filed by Nigon Richard
- SEC Form DEFA14A filed by Celcuity Inc.
- SEC Form DEF 14A filed by Celcuity Inc.
- SEC Form 4 filed by Buller Richard E
- SEC Form 10-K filed by Celcuity Inc.
- Celcuity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
- Amendment: SEC Form SCHEDULE 13D/A filed by Celcuity Inc.
- Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call
Latest DGX
- SEC Form FWP filed by Quest Diagnostics Incorporated
- Quest Diagnostics Prices $500 Million of Senior Notes
- Executive Vice President & CFO Samad Sam was granted 108 shares, increasing direct ownership by 0.32% to 33,376 units (SEC Form 4)
- SVP for Diagnostic Services Plewman Patrick increased direct ownership by 0.32% to 15,247 units (SEC Form 4)
- Director Gregg Vicky B was granted 68 shares, increasing direct ownership by 0.40% to 17,172 units (SEC Form 4)
- Director Carter Robert B increased direct ownership by 0.26% to 2,711 units (SEC Form 4)
- Director Lassiter Wright Iii increased direct ownership by 0.07% to 9,063 units (SEC Form 4)
- SVP, Clinical Solutions Kuppusamy Karthik increased direct ownership by 0.29% to 13,490 units (SEC Form 4)
- SVP & Chief Commercial Officer Delaney Mark E increased direct ownership by 0.31% to 11,901 units (SEC Form 4)
- SEC Form 10-Q filed by Quest Diagnostics Incorporated